미용용 신경독소 시장 규모, 점유율, 성장 및 세계 산업 분석 : 종류별, 용도별, 지역별 인사이트와 예측(2026-2034년)

Growth Factors of aesthetic neurotoxin Market

The global aesthetic neurotoxin market is witnessing robust growth due to the increasing demand for minimally invasive cosmetic procedures, rising awareness of aesthetic treatments, and expanding medical tourism. According to Fortune Business Insights, the market was valued at USD 5.6 billion in 2025, is projected to reach USD 5.98 billion in 2026, and is expected to expand to USD 10.7 billion by 2034, representing a CAGR of 7.54% during 2026-2034. North America dominated the market in 2025 with a 51.68% share, driven by strong infrastructure, high adoption of cosmetic procedures, and innovative product launches.

Aesthetic neurotoxins, commonly known as botulinum toxins, are widely used in aesthetic medicine as alternatives to surgical procedures. These toxins help in reducing wrinkles, fine lines, and other signs of aging. The market's growth is further supported by increasing cosmetic tourism. For example, in Korea, the Ministry of Health and Welfare reported a 144.2% increase in foreign medical visitors, with dermatology and plastic surgery procedures accounting for over 50% of the treatments in 2023.

Market Dynamics

Market Drivers:

The surge in demand for minimally invasive procedures has been a key growth driver. Non-surgical procedures, particularly botulinum toxin treatments, gained popularity with 8,877,991 Botox procedures performed in 2022, reflecting a 23% increase in non-surgical aesthetic procedures. Rising disposable incomes and the normalization of cosmetic enhancements in younger populations further bolster the market.

Market Restraints:

The adverse effects of botulinum toxins, such as pain, swelling, droopy eyelids, and flu-like symptoms, and the high cost of procedures limit adoption. In the U.S., Botox treatment costs average USD 450 per session, with some treatments reaching USD 1,200, restricting access for lower-income populations.

Market Opportunities:

Ongoing research and development offers significant growth avenues. Companies are developing safer and more effective products to minimize adverse effects. For instance, in October 2023, AbbVie reported positive Phase 3 trial results for trenibotulinumtoxinE for glabellar lines, highlighting innovation potential in the market.

Market Challenges:

The prevalence of counterfeit products poses a significant risk, both to revenue and patient safety. The CDC reported 17 cases of adverse reactions in the U.S. in June 2024 due to counterfeit neurotoxin injections, highlighting regulatory and safety challenges.

Market Trends

• Technological Advancements: Recombinant botulinum toxins are emerging as safer, less immunogenic alternatives to traditional toxins. MingMed Biotechnology received US FDA approval for YY003 in September 2024, a liquid recombinant BoNT/A for glabellar lines.
• Medical Tourism Expansion: Growth in aesthetic tourism, particularly in Asia and the Middle East, is increasing market adoption.
• Strategic Collaborations: Key players focus on partnerships to expand distribution networks and access emerging markets.

Segmentation Analysis

By Application:

• Glabellar lines dominate the market due to clinical prevalence and high demand for cosmetic correction. Positive Phase IIIb RELAX trial results in January 2025 further support growth.
• Forehead wrinkles segment is gaining share after Merz Aesthetics' FDA approval of XEOMIN in July 2023 for treating multiple upper facial lines.
• Crow's feet are also growing due to rising cosmetic concerns and treatment adoption.

By End-User:

• Specialty & dermatology clinics lead, benefiting from medical tourism and comprehensive cosmetic services. For example, in December 2024, The Esthetic Clinics attracted 15% international patients.
• Hospitals & clinics also maintain significant market share due to adherence to strict safety protocols. In 2023, 24.5% of U.S. cosmetic procedures were conducted in hospitals.
• Others include research institutes and aesthetic spas, offering stable growth opportunities through R&D activities.

Regional Outlook

North America: Market value USD 2.89 billion in 2025, projected to reach USD 2.97 billion by 2026, led by U.S. high adoption rates and regulatory approvals. AbbVie submitted a BLA for trenibotulinumtoxinE in April 2025 for glabellar lines.

Europe: Driven by the elderly population and cosmetic procedures demand. U.K. market USD 0.12 billion by 2026, Germany USD 0.24 billion by 2026. Merz Aesthetics expanded XEOMIN across Europe in July 2023.

Asia Pacific: Projected to grow at the highest CAGR. Japan market USD 0.39 billion by 2026, China USD 0.99 billion, India USD 0.07 billion, supported by strategic collaborations like Huadong Medicine and ATGC Co., Ltd.

Latin America & Middle East & Africa: Substantial growth due to rising disposable incomes and new product launches. In June 2025, Daewoong Pharmaceutical launched NABOTA in Qatar, expanding GCC availability.

Competitive Landscape

Key players include AbbVie Inc., Ipsen Pharma, Merz Pharma, Hugel Inc., Evolus, GALDERMA, REVANCE, and Supernus Pharmaceuticals. The market is consolidated, driven by product innovation, strategic collaborations, and regulatory approvals. Notable developments include Allergan Aesthetics launching BOTOX Cosmetic for masseter muscle prominence in China in September 2024.

Conclusion

The aesthetic neurotoxin market is expected to grow from USD 5.6 billion in 2025 to USD 10.7 billion by 2034, driven by minimally invasive procedure demand, increasing cosmetic tourism, technological advancements, and strategic partnerships. North America leads globally, followed by Europe and Asia Pacific, while innovations in recombinant toxins and medical tourism adoption are key to future growth.

Segmentation By Application

• Forehead Wrinkles
• Glabellar Lines
• Crow's Feet
• Others

By End-User

• Specialty & Dermatology Clinics
• Hospitals & Clinics
• Others

By Region

• North America (By Application, End-User, and Country)
  • U.S. (By Application)
  • Canada (By Application)
• Europe (By Application, End-User, and Country)
  • Germany (By Application)
  • U.K. (By Application)
  • France (By Application)
  • Italy (By Application)
  • Spain (By Application)
  • Scandinavia (By Application)
  • Ukraine (By Application)
  • Rest of Europe (By Application)
• Asia Pacific (By Application, End-User, and Country /sub-region)
  • China (By Application)
  • India (By Application)
  • Japan (By Application)
  • Australia (By Application)
  • South Korea (By Application)
  • Thailand (By Application)
  • Taiwan (By Application)
  • Rest of the Asia Pacific (By Application)
• Latin America (By Application, End-User, and Country /sub-region)
  • Brazil (By Application)
  • Mexico (By Application)
  • Colombia (By Application)
  • Argentina (By Application)
  • Venezuela (By Application)
  • Chile (By Application)
  • Rest of Latin America (By Application)
• Middle East & Africa (By Application, End-User, and Country /sub-region)
  • UAE (By Application)
  • Saudi Arabia (By Application)
  • Rest of GCC (By Application)
  • South Africa (By Application)
  • Turkey (By Application)
  • Egypt (By Application)
  • Lebanon (By Application)
  • Iran (By Application)
  • Rest of the Middle East & Africa (By Application)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Overview of the Number of Aesthetic Procedures, By Key Countries
• 4.2. Overview of Price Analysis of Types of Aesthetic Procedures
• 4.3. Overview of Regulatory Scenario, By Key Countries
• 4.4. Overview of Reimbursement Scenario, By Key Countries
• 4.5. New Product Launches, By Key Players
• 4.6. Pipeline Analysis, By Key Players
• 4.7. Imports/Sales Overview of Key Aesthetic Neurotoxin Products Approved by MHLW (Japan)

5. Global Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Application
  • 5.1.1. Forehead Wrinkles
  • 5.1.2. Glabellar Lines
  • 5.1.3. Crow's Feet
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By End-User
  • 5.2.1. Specialty & Dermatology Clinics
  • 5.2.2. Hospitals & Clinics
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Latin America
  • 5.3.5. Middle East & Africa

6. North America Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Application
  • 6.1.1. Forehead Wrinkles
  • 6.1.2. Glabellar Lines
  • 6.1.3. Crow's Feet
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By End-User
  • 6.2.1. Specialty & Dermatology Clinics
  • 6.2.2. Hospitals & Clinics
  • 6.2.3. Others
• 6.3. Market Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
  • 6.3.2. Canada

7. Europe Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Application
  • 7.1.1. Forehead Wrinkles
  • 7.1.2. Glabellar Lines
  • 7.1.3. Crow's Feet
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By End-User
  • 7.2.1. Specialty & Dermatology Clinics
  • 7.2.2. Hospitals & Clinics
  • 7.2.3. Others
• 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.3.1. U.K.
  • 7.3.2. Germany
  • 7.3.3. France
  • 7.3.4. Spain
  • 7.3.5. Italy
  • 7.3.6. Scandinavia
  • 7.3.7. Ukraine
  • 7.3.8. Rest of Europe

8. Asia Pacific Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Application
  • 8.1.1. Forehead Wrinkles
  • 8.1.2. Glabellar Lines
  • 8.1.3. Crow's Feet
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By End-User
  • 8.2.1. Specialty & Dermatology Clinics
  • 8.2.2. Hospitals & Clinics
  • 8.2.3. Others
• 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.3.1. Japan
  • 8.3.2. China
  • 8.3.3. India
  • 8.3.4. Australia
  • 8.3.5. South Korea
  • 8.3.6. Thailand
  • 8.3.7. Taiwan
  • 8.3.8. Rest of Asia Pacific

9. Latin America Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Application
  • 9.1.1. Forehead Wrinkles
  • 9.1.2. Glabellar Lines
  • 9.1.3. Crow's Feet
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By End-User
  • 9.2.1. Specialty & Dermatology Clinics
  • 9.2.2. Hospitals & Clinics
  • 9.2.3. Others
• 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.3.1. Brazil
  • 9.3.2. Mexico
  • 9.3.3. Chile
  • 9.3.4. Colombia
  • 9.3.5. Rest of Latin America

10. Middle East & Africa Aesthetic Neurotoxin Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Application
  • 10.1.1. Forehead Wrinkles
  • 10.1.2. Glabellar Lines
  • 10.1.3. Crow's Feet
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By End-User
  • 10.2.1. Specialty & Dermatology Clinics
  • 10.2.2. Hospitals & Clinics
  • 10.2.3. Others
• 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.3.1. Egypt
  • 10.3.2. Iran
  • 10.3.3. Turkey
  • 10.3.4. Lebanon
  • 10.3.5. UAE
  • 10.3.6. Saudi Arabia
  • 10.3.7. South Africa
  • 10.3.8. Rest of Middle East and Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. AbbVie Inc. (Allergen Aesthetics)
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Ipsen Pharma
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Merz Pharma
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. HUGEL, Inc.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Evolus, Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. GALDERMA
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. REVANCE
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Supernus Pharmaceuticals, Inc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Medytox
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
    • 11.2.10.1. Overview
    • 11.2.10.2. Products
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)
  • 11.2.11. DAEWOONG PHARMACEUTICAL CO., LTD
    • 11.2.11.1. Overview
    • 11.2.11.2. Products
    • 11.2.11.3. SWOT Analysis
    • 11.2.11.4. Recent Developments
    • 11.2.11.5. Strategies
    • 11.2.11.6. Financials (Based on Availability)